Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latanoprost/netarsudil - Alcon

Drug Profile

Latanoprost/netarsudil - Alcon

Alternative Names: AR-13324/latanoprost; Latanoprost/AR-13324; Latanoprost/netarsudil-mesylate; Netarsudil and latanoprost ophthalmic solution - Alcon; Netarsudil-mesylate/latanoprost; Netarsudil/latanoprost; Netarsudil/latanoprost ophthalmic solution - Alcon; PG-324; Rocklatan; Roclanda; Roclatan; STN 1014000

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aerie Pharmaceuticals
  • Developer Alcon; Santen Pharmaceutical
  • Class Antiglaucomas; Cyclopentanes; Eye disorder therapies; Isoquinolines; Prostaglandins; Small molecules
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors; Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Ocular hypertension; Open-angle glaucoma
  • Registered Glaucoma

Most Recent Events

  • 31 Jan 2023 Registered for Glaucoma in Asia (Ophthalmic) (Santen Pharmaceutical pipeline; November 2023)
  • 31 Jan 2023 Launched for Ocular hypertension in Germany (Ophthalmic) (Santen Pharmaceutical pipeline, February 2023)
  • 31 Jan 2023 Launched for Open-angle glaucoma in Germany (Ophthalmic) (Santen Pharmaceutical pipeline, February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top